Leerink Partnrs Forecasts Alumis FY2029 Earnings

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at Leerink Partnrs issued their FY2029 earnings estimates for shares of Alumis in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($1.61) per share for the year. The consensus estimate for Alumis’ current full-year earnings is ($8.45) per share.

Several other equities research analysts have also recently issued reports on ALMS. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Alumis in a research note on Monday, January 6th. Robert W. Baird began coverage on shares of Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective on the stock. Oppenheimer assumed coverage on shares of Alumis in a research note on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Baird R W upgraded Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Alumis has an average rating of “Buy” and a consensus target price of $27.57.

Alumis Trading Down 4.3 %

ALMS opened at $7.13 on Thursday. Alumis has a 1 year low of $6.29 and a 1 year high of $13.53. The firm has a fifty day moving average price of $7.98 and a 200 day moving average price of $10.32.

Institutional Investors Weigh In On Alumis

Several institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in Alumis in the 3rd quarter worth $27,000. MetLife Investment Management LLC purchased a new position in Alumis in the third quarter valued at about $89,000. China Universal Asset Management Co. Ltd. acquired a new stake in Alumis during the 4th quarter valued at approximately $79,000. JPMorgan Chase & Co. purchased a new stake in Alumis during the 3rd quarter worth approximately $191,000. Finally, Barclays PLC acquired a new position in shares of Alumis in the 3rd quarter valued at approximately $197,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.